Immunotherapy may be the way to tackle malignant pleural mesothelioma (MPM) after relapse, a new Phase 2 trial suggests. Using Opdivo (nivolumab) alone or in combination with…
Read More
Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell…
Read More
Adding nintedanib to chemotherapy led to a 64 percent increase in the time it took for mesothelioma patients’ disease to progress, compared with chemo alone,…
Read More
The calcium-binding protein calretinin is useful as a blood-based biomarker with high sensitivity to detect malignant mesothelioma, finds a study, “Calretinin as a blood-based biomarker for mesothelioma,” that…
Read More
A study has tried to overcome the challenges in the diagnosis of patients with malignant pleural mesothelioma (MPM) through the detection of two biomarkers in pleural…
Read More
Whole exome sequencing of asbestos-induced mouse models of malignant mesothelioma (MM) is a genuine representation of human mesothelioma and is a valuable tool for further…
Read More
Last year’s progress in preventing, diagnosing and treating all forms of lung cancer, including mesothelioma, is summarized in the second annual edition of the report, “Scientific Advances…
Read More
European researchers have identified two microRNAs, or small non-coding RNA molecules, that can be used to predict outcomes of malignant pleural mesothelioma, in an international study that…
Read More
Aggressive malignant peritoneal mesothelioma responds to treatment with Alimta (pemetrexed) and Platinol (cisplatin) chemotherapy, reports a study examining patient outcomes. But more studies are needed to…
Read More
A key approach to treating cancer these days is engineering immune T-cells to produce receptors on their surfaces that recognize cancer, so that the T-cells…
Read More
